Self-Assembled Multivalent Aptamer Nanoparticles with Potential CAR-like Characteristics Could Activate T Cells and Inhibit Melanoma Growth

Sharma, 2011, Novel cancer immunotherapy agents with survival benefit: recent successes and next steps, Nat. Rev. Cancer, 11, 805, 10.1038/nrc3153 Chen, 2013, Molecular mechanisms of T cell co-stimulation and co-inhibition, Nat. Rev. Immunol., 13, 227, 10.1038/nri3405 Sharma, 2015, Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential, Cell, 161, 205, 10.1016/j.cell.2015.03.030 Kochenderfer, 2010, Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19, Blood, 116, 4099, 10.1182/blood-2010-04-281931 Porter, 2011, Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia, N. Engl. J. Med., 365, 725, 10.1056/NEJMoa1103849 Weijtens, 1996, Single chain Ig/gamma gene-redirected human T lymphocytes produce cytokines, specifically lyse tumor cells, and recycle lytic capacity, J. Immunol., 157, 836, 10.4049/jimmunol.157.2.836 Carpenito, 2009, Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains, Proc. Natl. Acad. Sci. USA, 106, 3360, 10.1073/pnas.0813101106 Pegram, 2012, Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning, Blood, 119, 4133, 10.1182/blood-2011-12-400044 June, 2015, Adoptive cellular therapy: a race to the finish line, Sci. Transl. Med., 7, 280ps7, 10.1126/scitranslmed.aaa3643 Kochenderfer, 2013, Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors, Nat. Rev. Clin. Oncol., 10, 267, 10.1038/nrclinonc.2013.46 Mazzarella, 2014, Tales from the Jazz ASH: highlights from the 2013 American Society of Haematology meeting, Ecancermedicalscience, 8, 390 Grupp, 2013, Chimeric antigen receptor-modified T cells for acute lymphoid leukemia, N. Engl. J. Med., 368, 1509, 10.1056/NEJMoa1215134 Ellington, 1990, In vitro selection of RNA molecules that bind specific ligands, Nature, 346, 818, 10.1038/346818a0 Tuerk, 1990, Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase, Science, 249, 505, 10.1126/science.2200121 Groher, 2016, In vitro selection of antibiotic-binding aptamers, Methods, 106, 42, 10.1016/j.ymeth.2016.05.008 Bock, 1992, Selection of single-stranded DNA molecules that bind and inhibit human thrombin, Nature, 355, 564, 10.1038/355564a0 Lou, 2009, Micromagnetic selection of aptamers in microfluidic channels, Proc. Natl. Acad. Sci. USA, 106, 2989, 10.1073/pnas.0813135106 Shangguan, 2006, Aptamers evolved from live cells as effective molecular probes for cancer study, Proc. Natl. Acad. Sci. USA, 103, 11838, 10.1073/pnas.0602615103 Wang, 2003, Single-stranded DNA aptamers that bind differentiated but not parental cells: subtractive systematic evolution of ligands by exponential enrichment, J. Biotechnol., 102, 15, 10.1016/S0168-1656(02)00360-7 Li, 2009, Identification of an aptamer targeting hnRNP A1 by tissue slide-based SELEX, J. Pathol., 218, 327, 10.1002/path.2543 Röthlisberger, 2018, Aptamer chemistry, Adv. Drug Deliv. Rev., 134, 3, 10.1016/j.addr.2018.04.007 Han, 2013, In vitro selection of RNA aptamer specific to Salmonella typhimurium, J. Microbiol. Biotechnol., 23, 878, 10.4014/jmb.1212.12033 Liu, 2004, Screening of functional antidotes of RNA aptamers against bovine thrombin, FEBS Lett., 562, 125, 10.1016/S0014-5793(04)00197-8 Kaiser, 2006, Antivascular endothelial growth factor agents and their development: therapeutic implications in ocular diseases, Am. J. Ophthalmol., 142, 660, 10.1016/j.ajo.2006.05.061 Kraus, 1998, Cutting edge: novel RNA ligands able to bind CD4 antigen and inhibit CD4+ T lymphocyte function, J. Immunol., 160, 5209, 10.4049/jimmunol.160.11.5209 Wheeler, 2013, Durable knockdown and protection from HIV transmission in humanized mice treated with gel-formulated CD4 aptamer-siRNA chimeras, Mol. Ther., 21, 1378, 10.1038/mt.2013.77 Santulli-Marotto, 2003, Multivalent RNA aptamers that inhibit CTLA-4 and enhance tumor immunity, Cancer Res., 63, 7483 Pastor, 2013, CD28 aptamers as powerful immune response modulators, Mol. Ther. Nucleic Acids, 2, e98, 10.1038/mtna.2013.26 Dollins, 2008, Assembling OX40 aptamers on a molecular scaffold to create a receptor-activating aptamer, Chem. Biol., 15, 675, 10.1016/j.chembiol.2008.05.016 Prodeus, 2015, Targeting the PD-1/PD-L1 Immune Evasion Axis With DNA Aptamers as a Novel Therapeutic Strategy for the Treatment of Disseminated Cancers, Mol. Ther. Nucleic Acids, 4, e237, 10.1038/mtna.2015.11 Chauveau, 2007, Binding of an aptamer to the N-terminal fragment of VCAM-1, Bioorg. Med. Chem. Lett., 17, 6119, 10.1016/j.bmcl.2007.09.046 Jenison, 1998, Oligonucleotide inhibitors of P-selectin-dependent neutrophil-platelet adhesion, Antisense Nucleic Acid Drug Dev., 8, 265, 10.1089/oli.1.1998.8.265 Liu, 2010, Aptamer-based electrochemical biosensor for interferon gamma detection, Anal. Chem., 82, 8131, 10.1021/ac101409t Kang, 2008, Combinatorial selection of a single stranded DNA thioaptamer targeting TGF-beta1 protein, Bioorg. Med. Chem. Lett., 18, 1835, 10.1016/j.bmcl.2008.02.023 Boomer, 2005, Conjugation to polyethylene glycol polymer promotes aptamer biodistribution to healthy and inflamed tissues, Oligonucleotides, 15, 183, 10.1089/oli.2005.15.183 Shu, 2011, Thermodynamically stable RNA three-way junction for constructing multifunctional nanoparticles for delivery of therapeutics, Nat. Nanotechnol., 6, 658, 10.1038/nnano.2011.105 Levine, 2016, Global Manufacturing of CAR T Cell Therapy, Mol. Ther. Methods Clin. Dev., 4, 92, 10.1016/j.omtm.2016.12.006 Brentjens, 2010, Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial, Mol. Ther., 18, 666, 10.1038/mt.2010.31 Maude, 2018, Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia, N. Engl. J. Med., 378, 439, 10.1056/NEJMoa1709866 Morgan, 2010, Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2, Mol. Ther., 18, 843, 10.1038/mt.2010.24 Shimabukuro-Vornhagen, 2018, Cytokine release syndrome, J. Immunother. Cancer, 6, 56, 10.1186/s40425-018-0343-9 Rusconi, 2002, RNA aptamers as reversible antagonists of coagulation factor IXa, Nature, 419, 90, 10.1038/nature00963 Pastor, 2011, Targeting 4-1BB costimulation to disseminated tumor lesions with bi-specific oligonucleotide aptamers, Mol. Ther., 19, 1878, 10.1038/mt.2011.145 Boltz, 2011, Bi-specific aptamers mediating tumor cell lysis, J. Biol. Chem., 286, 21896, 10.1074/jbc.M111.238261 Im, 2016, Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy, Nature, 537, 417, 10.1038/nature19330 Kamphorst, 2017, Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent, Science, 355, 1423, 10.1126/science.aaf0683 Gross, 2016, Therapeutic Potential of T Cell Chimeric Antigen Receptors (CARs) in Cancer Treatment: Counteracting Off-Tumor Toxicities for Safe CAR T Cell Therapy, Annu. Rev. Pharmacol. Toxicol., 56, 59, 10.1146/annurev-pharmtox-010814-124844 Mercier, 2017, Selection of Nucleic Acid Aptamers Targeting Tumor Cell-Surface Protein Biomarkers, Cancers (Basel), 9, E69, 10.3390/cancers9060069